following a full submission assessed under the orphan medicine process:
lutetium (177Lu) oxodotreotide (Lutathera®) is accepted for use within NHSScotland.
Indication under review: for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.
In an open-label, phase III study, lutetium (177Lu) oxodotreotide significantly improved progression-free survival compared with a high dose somatostatin analogue in patients with progressive midgut neuroendocrine tumours.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice334KB (PDF)
- Medicine name:
- lutetium 177Lu oxodotreotide (Lutathera)
- SMC ID:
- Unresectable or metastatic, progressive, well differentiated (G1 and G2) somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours in adults.
- Pharmaceutical company
- Advanced Accelerator Applications
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 09 July 2018